[
  {
    "ts": null,
    "headline": "Prediction: PTC Will Soar Over the Next 3 Years. Here's 1 Reason Why.",
    "summary": "This software company's underlying growth rate is a lot stronger than the headline numbers indicate.",
    "url": "https://finnhub.io/api/news?id=cb6a5791335b8789d5d8e8d2e56efc5e7e38a3316b2b960d0cf040f57a490eff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756850267,
      "headline": "Prediction: PTC Will Soar Over the Next 3 Years. Here's 1 Reason Why.",
      "id": 136613594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "This software company's underlying growth rate is a lot stronger than the headline numbers indicate.",
      "url": "https://finnhub.io/api/news?id=cb6a5791335b8789d5d8e8d2e56efc5e7e38a3316b2b960d0cf040f57a490eff"
    }
  },
  {
    "ts": null,
    "headline": "RareMed Announces Expansion of Relationship with PTC Therapeutics",
    "summary": "RareMed Solutions®, the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationship with PTC Therapeutics™ with the launch of non-commercial pharmacy dispensing services for PTC's therapy, Sephience™. The recent approval of Sephience by the FDA marks a significant milestone in the treatment of phenylketonuria (PKU) for both adult and pediatric patients. This new therapy, developed by PTC, has the potential to transform the lives of tho",
    "url": "https://finnhub.io/api/news?id=c3cec0048e6254a0b8eef6236ace032f5f8a99fd43151ffd1025c3d6489d43b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756828380,
      "headline": "RareMed Announces Expansion of Relationship with PTC Therapeutics",
      "id": 136613595,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "RareMed Solutions®, the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationship with PTC Therapeutics™ with the launch of non-commercial pharmacy dispensing services for PTC's therapy, Sephience™. The recent approval of Sephience by the FDA marks a significant milestone in the treatment of phenylketonuria (PKU) for both adult and pediatric patients. This new therapy, developed by PTC, has the potential to transform the lives of tho",
      "url": "https://finnhub.io/api/news?id=c3cec0048e6254a0b8eef6236ace032f5f8a99fd43151ffd1025c3d6489d43b7"
    }
  },
  {
    "ts": null,
    "headline": "Q2 Design Software Earnings: PTC (NASDAQ:PTC) Impresses",
    "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the design software industry, including PTC (NASDAQ:PTC) and its peers.",
    "url": "https://finnhub.io/api/news?id=547da5b0b8d6d9de303c0ea01b327e041d38c6cf2c987efd21a4832e0b7363f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756787578,
      "headline": "Q2 Design Software Earnings: PTC (NASDAQ:PTC) Impresses",
      "id": 136604563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the design software industry, including PTC (NASDAQ:PTC) and its peers.",
      "url": "https://finnhub.io/api/news?id=547da5b0b8d6d9de303c0ea01b327e041d38c6cf2c987efd21a4832e0b7363f3"
    }
  }
]